These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 30711965)

  • 41. National Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.
    Calthorpe L; Romero-Hernandez F; Casey M; Nunez M; Conroy PC; Hirose K; Kim A; Kirkwood K; Maker AV; Corvera C; Nakakura E; Alseidi A; Adam MA
    Ann Surg Oncol; 2023 Aug; 30(8):5119-5129. PubMed ID: 37140748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Baratti D; Vaira M; Kusamura S; D'Amico S; Balestra MR; Cioppa T; Mingrone E; De Simone M; Deraco M
    Eur J Surg Oncol; 2010 Nov; 36(11):1047-53. PubMed ID: 20832234
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Deraco M; Baratti D; Hutanu I; Bertuli R; Kusamura S
    Ann Surg Oncol; 2013 Apr; 20(4):1093-100. PubMed ID: 23456386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
    Yan TD; Deraco M; Baratti D; Kusamura S; Elias D; Glehen O; Gilly FN; Levine EA; Shen P; Mohamed F; Moran BJ; Morris DL; Chua TC; Piso P; Sugarbaker PH
    J Clin Oncol; 2009 Dec; 27(36):6237-42. PubMed ID: 19917862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Five reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal mesotheliomia [corrected].
    Sugarbaker PH
    Ann Surg Oncol; 2010 Jun; 17(6):1710-2; author reply 1713-4. PubMed ID: 20354799
    [No Abstract]   [Full Text] [Related]  

  • 46. Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study.
    Madsen AH; Ladekarl M; Villadsen GE; Grønbæk H; Sørensen MM; Stribolt K; Verwaal VJ; Iversen LH
    Ann Surg Oncol; 2018 Feb; 25(2):422-430. PubMed ID: 29214450
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
    Vaira M; Robella M; Mellano A; Sottile A; De Simone M
    Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of prognostic factors of patients with malignant peritoneal mesothelioma.
    Yin W; Zheng G; Yang K; Song H; Liang Y
    World J Surg Oncol; 2018 Mar; 16(1):44. PubMed ID: 29506546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and surgical outcomes of patients with peritoneal mesothelioma discussed at a monthly national multidisciplinary team video-conference meeting.
    Brandl A; Westbrook S; Nunn S; Arbuthnot-Smith E; Mulsow J; Youssef H; Carr N; Tzivanakis A; Dayal S; Mohamed F; Moran BJ; Cecil T
    BJS Open; 2020 Apr; 4(2):260-267. PubMed ID: 32003132
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Principles of Surgical Management of Peritoneal Mesothelioma.
    Steadman JA; Grotz TE
    J Natl Compr Canc Netw; 2023 Sep; 21(9):981-986. PubMed ID: 37673112
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mesothelioma in children and adolescents: the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) contribution.
    Orbach D; André N; Brecht IB; López Almaraz R; Ben-Ami T; Vermersch S; Carton M; Virgone C; Bisogno G; Schneider DT; Bajciova V; Reguerre Y; Galateau-Salle F; Stachowicz-Stencel T; Dvir R; Rees H; Bien E; Ferrari A; Ben Arush M
    Eur J Cancer; 2020 Nov; 140():63-70. PubMed ID: 33049597
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies.
    Klos D; Riško J; Stašek M; Loveček M; Hanuliak J; Skalický P; Lemstrová R; Mohelníková BD; Študentová H; Neoral Č; Melichar B
    Cas Lek Cesk; 2018 Dec; 157(8):419-428. PubMed ID: 30754979
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
    Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
    Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multicystic peritoneal mesothelioma treated with cytoreductive surgery followed or not by hyperthermic intraperitoneal chemotherapy: results from a large multicentric cohort.
    Kepenekian V; Péron J; Goéré D; Sgarbura O; Delhorme JB; Eveno C; Benzerdjeb N; Bonnefoy I; Villeneuve L; Rousset P; Abboud K; Pocard M; Glehen O;
    Int J Hyperthermia; 2021; 38(1):805-814. PubMed ID: 34039244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comprehensive review of childbearing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Papageorgiou D; Manatakis DK; Papakonstantinou K; Kyriazanos ID
    Arch Gynecol Obstet; 2020 Oct; 302(4):793-799. PubMed ID: 32653946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases.
    Kyang LS; Alzahrani NA; Valle SJ; Rahman MK; Arrowaili A; Liauw W; Morris DL
    J Surg Oncol; 2019 Sep; 120(4):794-802. PubMed ID: 31309588
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Oliva GD; Laterza B; Deraco M
    Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia.
    Galan A; Rousset P; Mercier F; Képénékian V; Valette PJ; Glehen O; Passot G
    Eur J Surg Oncol; 2018 Nov; 44(11):1818-1823. PubMed ID: 30143249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy.
    Le Roy F; Gelli M; Hollebecque A; Honoré C; Boige V; Dartigues P; Benhaim L; Malka D; Ducreux M; Elias D; Goéré D
    Ann Surg Oncol; 2017 Nov; 24(12):3640-3646. PubMed ID: 28849389
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands.
    Razenberg LG; van Gestel YR; Creemers GJ; Verwaal VJ; Lemmens VE; de Hingh IH
    Eur J Surg Oncol; 2015 Apr; 41(4):466-71. PubMed ID: 25680955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.